Oklo shares have fallen sharply recently while remaining higher over the trailing year. A May 12, 2026 Q1 report showed a $33.1 million net loss versus $9.8 million a year earlier, with EPS of -$0.19 meeting expectations, yet the stock dropped after-hours. Liquidity improved to about $2.54 billion after a $1.2 billion equity raise. The NRC approved Oklo’s Principal Design Criteria for the Aurora power plant on an accelerated schedule, reducing regulatory uncertainty. Bull cases cite an own-and-operate model, isotope upside, and a 14 GW customer pipeline supported by major technology and infrastructure partners. A July 4, 2026 criticality milestone could validate fast-fission technology, while valuation, execution risk, and long commercialization timelines remain concerns.
"Our 24/7 Wall St. price target for Oklo is $98.78, implying 76.77% upside from a current price of $55.88. The recommendation is buy at a moderate 50% confidence level, reflecting genuine execution uncertainty."
"The recent swoon traces back to the May 12, 2026 Q1 report, which showed a $33.1 million net loss versus $9.8 million a year earlier. EPS of -$0.19 met expectations, but the stock still dropped 10.84% in after-hours trading. The fundamentals are quietly improving. Oklo now sits on roughly $2.54 billion in liquidity following a $1.2 billion equity raise."
"On May 6, 2026, the NRC approved Oklo's Principal Design Criteria for the Aurora powerhouse on an accelerated schedule, a regulatory de-risking event the market is underweighting. Bulls have a credible roadmap. Tigress Financial carries a Buy rating with a $130 target, citing Oklo's own-and-operate model, Aurora SMR, and isotope upside."
"The July 4, 2026 criticality milestone at the Groves Isotopes Test Reactor could validate fast-fission technology and re-rate the stock. Our bull-case scenario points to $180.53 within twelve months if Aurora regulatory progress accelerates and AI hyperscaler deals firm up into binding contracts. The bear case is real. Wolfe Research recently initiated at Peer Perform, citing valuation, execution risk, and a long commercialization timeline."
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]